» Articles » PMID: 17081806

Natural History of Patients Hospitalized for Management of Cirrhotic Ascites

Overview
Specialty Gastroenterology
Date 2006 Nov 4
PMID 17081806
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Since the International Ascites Club published the diagnostic criteria of refractory ascites (RA) and hepatorenal syndrome (HRS), there have been few studies assessing the natural history of ascites. The aims of this study were to define the natural history of cirrhotic ascites and to identify prognostic factors for dilutional hyponatremia (DH), RA, HRS, and survival.

Methods: Two hundred sixty-three consecutive cirrhotic patients were followed for 40.9 +/- 2.6 months after their first significant ascites.

Results: During follow-up 74 (28.1%) patients developed DH, 30 (11.4%) RA (diuretic-resistant in 2 cases and diuretic-intractable because of the development of diuretic-induced complications in 28 cases), and 20 (7.6%) HRS (type 1, 7; type 2, 13). The 5-year probability of DH, RA, and HRS development was 37.1%, 11.4%, and 11.4%, respectively. The probability of survival at 1 and 5 years was 85% and 56.5%, respectively. The independent predictors for survival were baseline age, baseline Child-Pugh score, and DH development. The 1-year probability of survival after developing DH, RA, and type 2 HRS was 25.6%, 31.6%, and 38.5%, respectively. In contrast, the mean survival was only 7 +/- 2 days in those patients developing type 1 HRS.

Conclusions: (1) The survival of cirrhotic patients with first episode of ascites is relatively high, and it is mainly influenced by age and Child-Pugh score at the time of ascites decompensation, as well as by DH development. (2) The probability of RA and HRS development is relatively low, but they are associated with a poor prognosis.

Citing Articles

Rejuvenating bone marrow hematopoietic reserve prevents regeneration failure and hepatic decompensation in animal model of cirrhosis.

Nautiyal N, Maheshwari D, Kumar D, Rao E, Tripathi D, Kumar S Front Immunol. 2024; 15:1439510.

PMID: 39188716 PMC: 11345600. DOI: 10.3389/fimmu.2024.1439510.


Physiological network approach to prognosis in cirrhosis: A shifting paradigm.

Oyelade T, Moore K, Mani A Physiol Rep. 2024; 12(13):e16133.

PMID: 38961593 PMC: 11222171. DOI: 10.14814/phy2.16133.


The hepatocellular carcinoma risk in patients with HBV-related cirrhosis: a competing risk nomogram based on a 4-year retrospective cohort study.

Guo D, Li J, Zhao P, Mei T, Li K, Zhang Y Front Oncol. 2024; 14:1398968.

PMID: 38817899 PMC: 11137271. DOI: 10.3389/fonc.2024.1398968.


Application of metagenomic next-generation sequencing in optimizing the diagnosis of ascitic infection in patients with liver cirrhosis.

Shi P, Liu J, Liang A, Zhu W, Fu J, Wu X BMC Infect Dis. 2024; 24(1):503.

PMID: 38769522 PMC: 11107059. DOI: 10.1186/s12879-024-09396-9.


Acute and non-acute decompensation of liver cirrhosis (47/130).

Schulz M, Angeli P, Trebicka J Liver Int. 2024; 45(3):e15861.

PMID: 38426268 PMC: 11815624. DOI: 10.1111/liv.15861.